These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication. Minor PD Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727 [TBL] [Abstract][Full Text] [Related]
23. [VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS IN RUSSIAN FEDERATION DURING THE PERIOD OF CHANGES IN VACCINATION SCHEDULE (2006-2013 yy.)]. Ivanova OE; Eremeeva TP; Morozova NS; Shakaryan AK; Gmyl AP; Yakovenko ML; Korotkova EA; Chernjavskaja OP; Baykova OY; Silenova OV; Krasota AY; Krasnoproshina LI; Mustafina AN; Kozlovskaja LI Vopr Virusol; 2016; 61(1):9-15. PubMed ID: 27145594 [TBL] [Abstract][Full Text] [Related]
24. Changing poliovirus vaccine policy can be controversial at best. Faden H Adv Pediatr Infect Dis; 1997; 13():305-32. PubMed ID: 9544317 [No Abstract] [Full Text] [Related]
25. Antibody response of children immunized with poliovaccines: an evaluation using two strains of poliovirus type 1. Deshpande JM; Dave KH Indian J Med Res; 1992 Sep; 95():216-20. PubMed ID: 1335965 [TBL] [Abstract][Full Text] [Related]
26. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA; Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714 [TBL] [Abstract][Full Text] [Related]
27. Poliomyelitis immunity status in Italian and foreign subjects. Tanzi ML; Bracchi U; Affanni P; Dall'Argine A; Bombarda G; Bellelli E Ann Ig; 1992; 4(4):191-7. PubMed ID: 1284576 [No Abstract] [Full Text] [Related]
28. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424 [TBL] [Abstract][Full Text] [Related]
30. Poliovirus vaccine and vaccine-derived polioviruses. Plotkin SA N Engl J Med; 2010 Nov; 363(19):1870; author reply 1870-1. PubMed ID: 21047242 [No Abstract] [Full Text] [Related]
31. The outbreak of poliomyelitis in Finland in 1984-1985: significance of antigenic variation of type 3 polioviruses and site specificity of antibody responses in antipolio immunizations. Hovi T Adv Virus Res; 1989; 37():243-75. PubMed ID: 2557759 [No Abstract] [Full Text] [Related]
32. The polio eradication effort has been a great success--let's finish it and replace it with something even better. Kimman TG; Boot H Lancet Infect Dis; 2006 Oct; 6(10):675-8. PubMed ID: 17008176 [TBL] [Abstract][Full Text] [Related]
33. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines. Xiao Y; Daniell H Vaccine; 2017 Sep; 35(40):5418-5425. PubMed ID: 28111147 [TBL] [Abstract][Full Text] [Related]
34. The feasibility of identifying children with primary immunodeficiency disorders: preparation for the polio post-eradication era in Bangladesh. Sazzad HM; Rainey JJ; Mach O; Sutter R; Diordista S; Kawser CA; Mobarak R; Alam D; Chowdhury MA; Hossain MJ; Hasan AS; Luby SP Vaccine; 2012 Aug; 30(36):5396-400. PubMed ID: 22728220 [TBL] [Abstract][Full Text] [Related]
35. The problems of poliovirus immunization. Fulginiti VA Hosp Pract; 1980 Aug; 15(8):61-7. PubMed ID: 6249713 [No Abstract] [Full Text] [Related]
36. sIPV process development for costs reduction. Thomassen YE; Bakker WA Vaccine; 2015 Aug; 33(35):4307-12. PubMed ID: 25858858 [TBL] [Abstract][Full Text] [Related]
37. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Pliaka V; Kyriakopoulou Z; Markoulatos P Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246 [TBL] [Abstract][Full Text] [Related]
38. Polio eradication: the OPV paradox. Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339 [TBL] [Abstract][Full Text] [Related]
39. New recommendations for poliovirus vaccination. Combination regimen captures best effects of available vaccines. Conrad DA; Jenson HB Postgrad Med; 1997 Nov; 102(5):45-8, 51-3, 59-60 passim. PubMed ID: 9385331 [TBL] [Abstract][Full Text] [Related]
40. When can we stop using oral poliovirus vaccine? Hull HF; Minor PD J Infect Dis; 2005 Dec; 192(12):2033-5. PubMed ID: 16288363 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]